In this article, we will list the 5 Best Medical Device Stocks to Invest In Right Now. Please visit 10 Best Medical Device Stocks to Invest In Right Now if you would like to see the extended list and the methodology behind it.
5. Edwards Lifesciences Corporation (NYSE:EW)
Edwards Lifesciences Corporation (NYSE:EW) is one of the best medical device stocks to invest in right now. Barclays raised the price target on Edwards Lifesciences Corporation (NYSE:EW) to $110 from $104 on April 27, reaffirming an Overweight rating on the shares. The rating update came after the company’s fiscal Q1 earnings, with the firm telling investors in a research note that Edwards Lifesciences Corporation’s (NYSE:EW) quarter showed share gains in Europe and the United States.
In its financial results for Q1 released on April 23, Edwards Lifesciences Corporation (NYSE:EW) reported that fiscal Q1 sales rose 16.7% to $1.65 billion, while constant currency sales grew 12.7%. TAVR sales in the quarter rose 14.4% to $1.20 billion, while constant currency sales grew 11.0%. The company further reported that fiscal Q1 TMTT sales reached $173 million, driven by repair and replacement therapies.
Edwards Lifesciences Corporation (NYSE:EW) raised FY26 constant currency sales growth guidance to 9% to 11% from 8% to 10%, and also raised the FY26 adjusted EPS guidance midpoint, with a new range of $2.95 to $3.05 from $2.90 to $3.05.
Edwards Lifesciences Corporation (NYSE:EW) is involved in patient-focused medical innovations for heart disease and critical care monitoring. The company’s products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. Its operations are divided into the following geographical segments: the United States, Europe, Japan, and the Rest of the World.
4. Stryker Corporation (NYSE:SYK)
Stryker Corporation (NYSE:SYK) is one of the best medical device stocks to invest in right now. Truist cut the price target on Stryker Corporation (NYSE:SYK) to $380 from $395 on April 15, reaffirming a Hold rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 results in MedTech, with the firm stating that it anticipates fiscal Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes. It further stated in a research note that a premium valuation is justified for the stock given its view of the company’s high-quality, above-average revenue growth profile. However, it also prefers to have higher conviction in EPS upside and faster earnings growth potential.
Stryker Corporation (NYSE:SYK) also received a rating update from BTIG on April 13. The firm lowered the price target on the stock to $397 from $412 and maintained a Buy rating on the shares. The rating update came as part of a broader research name on Medical Technology.
Stryker Corporation (NYSE:SYK) is a medical technology company that offers products and services that help improve patient and health outcomes. Its operations are divided into the MedSurg and Neurotechnology and the Orthopedics and Spine segments.
3. DexCom, Inc. (NASDAQ:DXCM)
DexCom, Inc. (NASDAQ:DXCM) is one of the best medical device stocks to invest in right now. BTIG cut the price target on DexCom, Inc. (NASDAQ:DXCM) to $80 from $85 on April 13 and reaffirmed a Buy rating on the shares. The rating update came as part of a broader research note on Medical Technology, with the firm updating its models to take into account CMS having announced its proposed rule for the FY27 inpatient prospective payment system. The firm told investors in a research note that this includes, among other things, preliminary commentary and decisions regarding new technology add-on payments.
DexCom, Inc. (NASDAQ:DXCM) is set to release its fiscal Q1 2026 financial results on Thursday, April 30, after market close. For reference, in its fiscal Q4 and full year 2025 results, the company reiterated its FY26 guidance and expects revenue in the $5.16 – $5.25 billion range with around 11-13% growth, non-GAAP gross profit margin of approximately 63-64%, non-GAAP operating margin of approximately 22-23%, and adjusted EBITDA margin of approximately 30-31%.
DexCom, Inc. (NASDAQ:DXCM) is a medical device company that manufactures continuous glucose monitoring (CGM) systems to allow real-time health management control. It offers various medical devices and products, including Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.
2. Abbott Laboratories (NYSE:ABT)
Abbott Laboratories (NYSE:ABT) is one of the best medical device stocks to invest in right now. Abbott Laboratories (NYSE:ABT) announced on April 28 that it received the U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0 Software. Management stated that the milestone marks a considerable step forward for the company, bringing coronary imaging and AI-automated insights together in one system to support better patient outcomes and help reduce risks. It further reported that the Ultreon 3.0 is an AI-powered imaging platform that employs optical coherence tomography to provide real-time planning guidance to doctors while performing minimally invasive procedures to open blocked heart arteries, which is known as percutaneous coronary intervention.
David M. Leistner, interventional cardiologist, Clinic for Cardiology and Angiology, Charité Campus Benjamin-Franklin (CBF) in Berlin, Germany, stated that Abbott Laboratories’ (NYSE:ABT) Ultreon 3.0 offers a single, AI-driven platform able to quickly and easily capture the images required by physicians to fully understand the size and angle of the blockage, creating an actionable plan to help the patient.
Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells healthcare products. Its business segments include Diagnostic Products, Established Pharmaceutical Products, Medical Devices, and Nutritional Products.
1. Boston Scientific Corporation (NYSE:BSX)
Boston Scientific Corporation (NYSE:BSX) is one of the best medical device stocks to invest in right now. Argus cut the price target on Boston Scientific Corporation (NYSE:BSX) to $95 from $115 on April 27, reaffirming a Buy rating on the shares. The rating update came after the company’s fiscal Q1 earnings and guidance cut, with the firm telling investors in a research note that the stock has recently underperformed the broader market. However, it added that the company remains well-positioned in high-growth areas such as cardiovascular, electrophysiology, and neuromodulation, with the management setting more achievable objectives by cutting its outlook. Argus believes that Boston Scientific Corporation’s (NYSE:BSX) price weakness creates a buying opportunity.
Boston Scientific Corporation (NYSE:BSX) also received a rating update from Truist on April 15, with the firm cutting the price target on the stock to $90 from $92 while reaffirming a Buy rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 results in MedTech, with the firm stating that it expects fiscal Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes.
Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.
While we acknowledge the potential of BSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
